Form 8-K - Current report:
SEC Accession No. 0001213900-24-079165
Filing Date
2024-09-17
Accepted
2024-09-17 08:00:32
Documents
15
Period of Report
2024-09-16
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea021470501-8k_allarity.htm   iXBRL 8-K 25348
2 PRESS RELEASE, DATED SEPTEMBER 16, 2024. ea021470501ex99-1_allarity.htm EX-99.1 15973
3 GRAPHIC image_001.jpg GRAPHIC 3027
  Complete submission text file 0001213900-24-079165.txt   231330

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE allr-20240916.xsd EX-101.SCH 3051
5 XBRL LABEL FILE allr-20240916_lab.xml EX-101.LAB 34916
6 XBRL PRESENTATION FILE allr-20240916_pre.xml EX-101.PRE 22813
17 EXTRACTED XBRL INSTANCE DOCUMENT ea021470501-8k_allarity_htm.xml XML 3964
Mailing Address 24 SCHOOL ST., 2ND FLOOR BOSTON MA 02108
Business Address 24 SCHOOL ST., 2ND FLOOR BOSTON MA 02108 401-426-4664
Allarity Therapeutics, Inc. (Filer) CIK: 0001860657 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41160 | Film No.: 241302614
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)